Business · Companies · 3 hrs ago
GemVax appoints Lee Jae-hong as chief medical officer
GemVax has appointed neurologist Lee Jae-hong as its new chief medical officer to lead clinical development and operations in its biotechnology business.
Lee spent more than 30 years at Seoul Asan Medical Center, where he worked in neurology and led its Parkinson’s and Alzheimer’s center.
He will oversee development of treatments for conditions including progressive supranuclear palsy and ALS, also known as Lou Gehrig’s disease.
These are difficult-to-treat neurodegenerative diseases, and the company says they are among its main drug-development programs.
Lee has published 253 academic papers and held leadership roles in South Korea’s dementia research and policy work.
GemVax plans to strengthen its clinical trials in Korea and abroad and develop its strategy for testing treatments in additional conditions; no trial results or timetable were announced.
GemVax has appointed Lee Jae-hong, a specialist in neurodegenerative diseases, as its chief medical officer.
Lee will lead clinical development and operations in the company’s bio business division.
He will oversee development of treatments for conditions including progressive supranuclear palsy and amyotrophic lateral sclerosis.
Lee worked in the neurology department at Asan Medical Center for more than 30 years.
GemVax said his appointment is expected to strengthen clinical development and support plans to expand treatment indications.
- Who
- GemVax and Lee Jae-hong, its newly appointed chief medical officer.
- What
- GemVax appointed Lee to lead clinical development and operations in its bio business division.
- When
- November 3, 2026.
- Where
- Not stated.
- Why
- Lee is expected to guide development of treatments for neurodegenerative diseases and strengthen clinical development.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Appointment
- Lee Jae-hong named chief medical officer
- Clinical role
- Lead clinical development and operations in GemVax’s bio business division
- Prior experience
- More than 30 years in the neurology department at Asan Medical Center
- Research
- 253 academic papers published in international journals
- Diseases
- Progressive supranuclear palsy and amyotrophic lateral sclerosis
What people are saying
We are pleased to bring on board a leading authority who has guided clinical practice and academia in neurodegenerative diseases for decades.
I will do my best to raise the quality and speed of clinical development, drawing on my clinical experience and expertise, so that we can provide practical treatment options to patients.